Prevention of Type 1 Diabetes with Major Histocompatibility Complex–Compatible and Nonmarrow Ablative Hematopoietic Stem Cell Transplants

TABLE 1

Hematopoietic cell chimerism posttransplantation

Recipient Preconditioning treatment (rad) Graft Transplanted cells Engrafted mice/ transplanted mice Donor-derived PBMCs
CD3+ (%) B220+ (%) Mac-1+/Gr-1+ (%)
NOD (n = 16) 950 C57BL/6.H-2g7 HSC 4,000 16/16 69.6 ± 8.0 96.9 ± 1.2 89.1 ± 16.7
NOD (n = 9) 700 C57BL/6.H-2g7 HSC 4,000 9/9 64.5 ± 5.6 90.6 ± 2.2 80.4 ± 12.1
NOD (n = 7) 950 C57BL/6.H-2g7 bone marrow 6 × 106 7/7 88.9 ± 3.3 98.9 ± 0.2 99.1 ± 0.6
NOD.SCID (n = 10) 300 C57BL/6.H-2g7 bone marrow 6 × 106 5/10* 99.8 ± 0.1 99.7 ± 0.2 97.8 ± 3.4
  • Data are means ± SD. NOD or NOD.SCID mice were 8–9 weeks old at the time they were conditioned for AHCT with radiation treatment. Recipients received either C57BL/6.H-2g7 HSC or bone marrow grafts. Donor blood chimerism was evaluated at ∼50 days’ posttransplant by FACS analysis with double staining using CD45.2 and lineage-specific labeled monoclonal antibodies.

  • *

    * Five mice died before chimerism evaluation. PBMCs, peripheral blood mononuclear cells.

This Article

  1. Diabetes vol. 54 no. 6 1770-1779